GlassScriptPhysician profile
Emma Ab Cabusao
NPI 1417911744
$5,158.13
in general payments reported to CMS, 2019-2025
32 companies · $1,010 in 2025
The $1,010 reported for 2025 was more than what 81% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,656 · 2020: $344 · 2021: $118 · 2022: $469 · 2023: $659 · 2024: $903 · 2025: $1,010.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,450 · Education: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,449.78 |
| Education | $120.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $783.99 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Lundbeck LLC | $513.15 | 2019-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $388.10 | 2019-2025 | Spravato |
| Teva Pharmaceuticals USA, INC. | $356.05 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $287.44 | 2022-2025 | Aristada, Lybalvi |
| Abbvie INC. | $258.91 | 2021-2025 | Vraylar |
| Corium, LLC | $257.73 | 2022-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $255.96 | 2019-2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $212.18 | 2021-2025 | Caplyta |
| Axsome Therapeutics, INC. | $209.88 | 2023-2025 | Auvelity, Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $202.54 | 2019-2024 | Trintellix |
| Tris Pharma INC | $179.12 | 2023-2025 | Dyanavel Xr |
| Neurocrine Biosciences, INC. | $150.39 | 2019-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $120.56 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $96.12 | 2024-2025 | Cobenfy |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $92.03 | 2019-2025 | Wellbutrin, Aplenzin |
| Almatica Pharma LLC | $83.53 | 2021-2024 | Loreev Xr |
| Shire North American Group INC | $81.00 | 2019 | |
| Jazz Pharmaceuticals INC. | $80.12 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $67.37 | 2022-2024 | Qelbree, Qelbree |
| Allergan, INC. | $66.07 | 2019-2020 | |
| Owp Pharmaceuticals, INC. | $66.03 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $55.27 | 2019-2023 | Jornay Pm |
| Merck Sharp & Dohme LLC | $52.77 | 2022-2023 | Belsomra |
| Collegium Pharmaceutical, INC. | $47.85 | 2025 | Jornay Pm |
| Vertical Pharmaceuticals, LLC | $44.44 | 2019-2020 | |
| Brainsway USA INC | $41.31 | 2022 | |
| Tms Neurohealth Centers INC. | $34.39 | 2025 | Tms Neurohealth Centers INC. |
| Adlon Therapeutics L.P. | $27.30 | 2020 | |
| Neos Therapeutics, LP | $17.29 | 2019 | |
| Idorsia Pharmaceuticals US INC | $15.99 | 2023 | Quviviq |
| Noven Therapeutics, LLC | $13.25 | 2024 | Xelstrym, Secuado |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emma Cabusao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.